Calcium glubionate

Identification

Name
Calcium glubionate
Accession Number
DB13142
Type
Small Molecule
Groups
Approved
Description

Calcium glubionate (or glubionate calcium) is a mineral supplement to prevent or treat low blood calcium levels in people who do not get enough calcium from their diets.

Structure
Thumb
Synonyms
  • (D-gluconato)(lactobionato)calcium
  • Calcium D-gluconate lactobionate
  • Calcium glubionate anhydrous
  • Glubionate calcium
Product Ingredients
IngredientUNIICASInChI Key
Calcium D-gluconate lactobionate monohydrate3CF7K0SD0Q12569-38-9OKRXSXDSNLJCRS-LMMYEKIPSA-L
Categories
UNII
93H20IU3DN
CAS number
97635-31-9
Weight
Average: 592.513
Monoisotopic: 592.1163697
Chemical Formula
C18H32CaO19
InChI Key
YPCRNBPOUVJVMU-DTRXJECDSA-L
InChI
InChI=1S/C12H22O12.C6H12O7.Ca/c13-1-3(15)10(7(18)8(19)11(21)22)24-12-9(20)6(17)5(16)4(2-14)23-12;7-1-2(8)3(9)4(10)5(11)6(12)13;/h3-10,12-20H,1-2H2,(H,21,22);2-5,7-11H,1H2,(H,12,13);/q;;+2/p-2/t3-,4-,5+,6-,7-,8-,9-,10-,12+;2-,3-,4+,5-;/m11./s1
IUPAC Name
{[(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-{[(2S,3R,4R,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}hexanoyl]oxy}calcio (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanoate
SMILES
OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(=O)O[Ca]OC(=O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@@H](O)[C@H]1O)[C@H](O)CO

Pharmacology

Indication

Calcium glubionate is indicated to treat conditions caused by low calcium levels such as bone loss (osteoporosis), weak bones (osteomalacia/rickets), decreased activity of the parathyroid gland (hypoparathyroidism), and a certain muscle disease (latent tetany). It may also be used in certain patients to make sure they are getting enough calcium (e.g., women who are pregnant, nursing, or postmenopausal, people taking certain medications such as phenytoin, phenobarbital, or prednisone).

Pharmacodynamics
Not Available
Mechanism of action

Essential for nervous, muscular, and skeletal systems. Maintain cell membrane and capillary permeability. Act as an activator in the transmission of nerve impulses and contraction of cardiac, skeletal, and smooth muscle. Essential for bone formation and blood coagulation.

Absorption

Minimal unless chronic, high doses; absorption predominantly in the duodenum and dependent on calcitriol and vitamin D; mean absorption of calcium intake varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, adults 25%); during pregnancy, calcium absorption doubles; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment (IOM 2011); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia

Volume of distribution

Primarily in bones, teeth

Protein binding

~40%, primarily to albumin

Metabolism
Not Available
Route of elimination

Primarily feces (75%; as unabsorbed calcium); urine (22%)

Half life
Not Available
Clearance
Not Available
Toxicity

Assess patient for nausea, vomiting, anorexia, thirst, severe constipation, paralytic ileus, and bradycardia

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinCalcium glubionate may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium glubionate may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium glubionate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Alfacalcidol.Approved, Nutraceutical
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium glubionate.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium glubionate.Approved
AmrinoneThe therapeutic efficacy of Amrinone can be decreased when used in combination with Calcium glubionate.Approved
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
AzimilideThe therapeutic efficacy of Azimilide can be decreased when used in combination with Calcium glubionate.Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium glubionate.Approved
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium glubionate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate.Approved, Withdrawn
BioallethrinThe therapeutic efficacy of Bioallethrin can be decreased when used in combination with Calcium glubionate.Approved, Experimental
CalcidiolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Calcium Acetate.Approved, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium glubionate.Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium glubionate.Experimental
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Ceftriaxone.Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium glubionate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Cholecalciferol.Approved, Nutraceutical
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
CinoxacinCalcium glubionate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinCalcium glubionate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium glubionate.Approved, Investigational, Vet Approved
CyclandelateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium glubionate.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Experimental
CymarinCalcium glubionate may increase the arrhythmogenic activities of Cymarin.Experimental
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium glubionate.Experimental
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium glubionate.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium glubionate.Approved
DeslanosideCalcium glubionate may increase the arrhythmogenic activities of Deslanoside.Approved
DigitoxinCalcium glubionate may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinCalcium glubionate may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Calcium glubionate may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium glubionate.Approved, Investigational
Dipotassium phosphateCalcium glubionate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium glubionate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium glubionate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium glubionate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium glubionate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium glubionate.Approved
EnoxacinCalcium glubionate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium glubionate.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Experimental
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Ergocalciferol.Approved, Nutraceutical
EstramustineCalcium glubionate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium glubionate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium glubionate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium glubionate.Withdrawn
Fish oilThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium glubionate.Approved, Nutraceutical
FleroxacinCalcium glubionate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlumequineCalcium glubionate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium glubionate.Approved
FluspirileneThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium glubionate.Approved, Investigational
GabapentinThe therapeutic efficacy of Gabapentin can be decreased when used in combination with Calcium glubionate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium glubionate.Investigational
GarenoxacinCalcium glubionate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium glubionate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium glubionate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GitoformateCalcium glubionate may increase the arrhythmogenic activities of Gitoformate.Experimental
GrepafloxacinCalcium glubionate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved, Investigational
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
Lanatoside CCalcium glubionate may increase the arrhythmogenic activities of Lanatoside C.Experimental
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium glubionate.Approved, Investigational
LevofloxacinCalcium glubionate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium glubionate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium glubionate.Experimental
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium glubionate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium glubionate.Approved
Lipoic AcidCalcium glubionate can cause a decrease in the absorption of Lipoic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Nutraceutical
LomefloxacinCalcium glubionate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LoperamideThe therapeutic efficacy of Loperamide can be decreased when used in combination with Calcium glubionate.Approved
Magnesium sulfateThe therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Calcium glubionate.Approved, Investigational, Vet Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
MentholThe therapeutic efficacy of Menthol can be decreased when used in combination with Calcium glubionate.Approved
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium glubionate.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
MetildigoxinCalcium glubionate may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium glubionate.Investigational, Withdrawn
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium glubionate.Approved, Investigational
MoxifloxacinCalcium glubionate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium glubionate.Investigational
Nalidixic AcidCalcium glubionate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium glubionate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium glubionate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium glubionate.Experimental
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium glubionate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium glubionate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium glubionate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium glubionate.Approved, Investigational
NorfloxacinCalcium glubionate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium glubionate.Approved
OfloxacinCalcium glubionate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium glubionate may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium glubionate.Experimental, Investigational
OuabainCalcium glubionate may increase the arrhythmogenic activities of Ouabain.Approved
Oxolinic acidCalcium glubionate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium glubionate.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium glubionate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium glubionate is combined with Paricalcitol.Approved, Investigational
PazufloxacinCalcium glubionate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium glubionate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCalcium glubionate may increase the arrhythmogenic activities of Peruvoside.Experimental
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium glubionate.Approved
Pipemidic acidCalcium glubionate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Piromidic acidCalcium glubionate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PolythiazidePolythiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium glubionate.Withdrawn
ProscillaridinCalcium glubionate may increase the arrhythmogenic activities of Proscillaridin.Experimental
PrulifloxacinCalcium glubionate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
QuinethazoneQuinethazone may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium glubionate.Approved, Investigational
RosoxacinCalcium glubionate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RufloxacinCalcium glubionate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SeletracetamThe therapeutic efficacy of Seletracetam can be decreased when used in combination with Calcium glubionate.Investigational
SitafloxacinCalcium glubionate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium glycerophosphateCalcium glubionate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphateCalcium glubionate can cause a decrease in the absorption of Sodium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SparfloxacinCalcium glubionate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium glubionate.Approved, Withdrawn
Technetium Tc-99m etidronateThe serum concentration of Technetium Tc-99m etidronate can be decreased when it is combined with Calcium glubionate.Approved
Technetium Tc-99m medronateThe serum concentration of Technetium Tc-99m medronate can be decreased when it is combined with Calcium glubionate.Approved
TemafloxacinCalcium glubionate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium glubionate.Experimental
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Calcium glubionate.Approved, Vet Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium glubionate.Investigational
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium glubionate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium glubionate.Approved, Investigational, Vet Approved
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium glubionate.Approved, Investigational
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium glubionate.Approved, Investigational
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium glubionate.Approved, Investigational
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium glubionate.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium glubionate.Approved
TrovafloxacinCalcium glubionate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium glubionate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium glubionate.Investigational
WIN 55212-2The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Calcium glubionate.Experimental
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium glubionate.Approved
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium glubionate.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium glubionate.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Drug Information [Link]
External Links
PubChem Compound
131704325
PubChem Substance
347829259
Wikipedia
Calcium_glubionate
ATC Codes
A12AA02 — Calcium glubionate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility47.2 mg/mLALOGPS
logP-2.5ALOGPS
logP-9.6ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)11.32ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count13ChemAxon
Polar Surface Area334.05 Å2ChemAxon
Rotatable Bond Count17ChemAxon
Refractivity107.1 m3·mol-1ChemAxon
Polarizability50.76 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 04, 2016 14:50 / Updated on June 02, 2018 09:45